SPY734.54+0.21%QQQ657.87+1.67%BTC/USD75,508.71−0.60%DIA509.39−0.95%GLD370.05−1.45%TLT81.89−0.05%

Premium Services

Premium Services

Sanofi SA

SNYNASDAQ

Trade with Public

Trade with Public

$45.61

-1.30-2.77%

Last update: Nov 6, 9:15 AM

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Dividends Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

Sanofi (SNY) Stock Price Target 2026 & Analyst Forecast - Benzinga

Sanofi (SNY) Stock Price Target 2026

The average analyst price target for Sanofi is $61, 33.7% above the current price. Of 8 analysts, 4 rate it Buy and 4 Hold. Targets range from $58 to $65. The latest change came on Jan 16, 2026, when UBS downgraded Sanofi from Buy to Neutral.

The Average Analyst Price Target for Sanofi is $61.

Price Target Range — 4 Quarters

Analyst Consensus — 8 Analysts

4Buy

4Hold

Consensus RatingBuy# Analysts8Avg. Consensus PT$61Upside to Avg. PT+33.7%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Sanofi Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jan 16, 2026	UBS	Matthew Weston	Downgrade	Buy→Neutral	—
Jan 6, 2026	Barclays	—	Downgrade	Overweight→Equal-Weight	—
Dec 9, 2025	Guggenheim	Seamus Fernandez	Downgrade	Buy→Neutral	—
Dec 8, 2025	JP Morgan	Richard Vosser	Downgrade	Overweight→Neutral	—
Oct 27, 2025	Jefferies	—	Assumes	Buy	—
Sep 8, 2025	Morgan Stanley	Mark Purcell	Upgrade	Equal-Weight→Overweight	$56→$58
Sep 2, 2025	Deutsche Bank	Emmanuel Papadakis	Upgrade	Hold→Buy	—
Aug 8, 2025	JP Morgan	Richard Vosser	Upgrade	Neutral→Overweight	—
Mar 21, 2025	Goldman Sachs	James Quigley	Initiate	Neutral	$65
Jul 26, 2024	Argus Research	Jasper Hellweg	PT Raise	Buy	$55→$60
Jan 23, 2024	Morgan Stanley	Mark Purcell	Initiate	Equal-Weight	$55

Analyst Ratings News

The Multiple Sclerosis Drug Race Just Got Hotter After Novartis’ Phase 3 Win

Novartis stock spikes 5% on positive Phase 3 REMODEL trial results for relapsing MS drug remibrutinib with no liver safety signals.

Vandana Singh

Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says

Sanofi discontinues Phase 3 riliprubart study for CIDP due to low efficacy. SNY stock ticks up. Read the market & analyst reaction.

Vandana Singh

Immunic's Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says

Stifel initiates coverage on Immunic (IMUX) with a Buy rating. Analysts see potential for VidoCa to disrupt the MS market via better safety.

Vandana Singh

March Inflation Set For Biggest Jump Since June 2022 — When CPI Spikes, These Stocks Fall

Trump, in January, said "inflation has been defeated." Wall Street is now bracing for a 0.9% monthly CPI surge — the steepest since June 2022.

Piero Cingari

Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst

William Blair starts Eupraxia at Outperform as the analyst flags unmet need and sizable market potential.

Vandana Singh

Dianthus Therapeutics Stock Rallies—Rare Disease Study Success Fuels Optimism

Dianthus Therapeutics shares jump after early success in a Phase 3 trial for CIDP treatment claseprubart, signaling potential progress toward approval.

Vandana Singh